Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Get Free Report) have received an average recommendation of "Buy" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $62.50.

Several research analysts recently issued reports on JSPR shares. Royal Bank of Canada cut their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. UBS Group started coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $38.00 target price for the company. JMP Securities reiterated a "market outperform" rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, March 11th. Finally, BMO Capital Markets initiated coverage on shares of Jasper Therapeutics in a research note on Friday, December 6th. They issued an "outperform" rating and a $63.00 price target for the company.

Jasper Therapeutics Trading Down 8.2 %

Shares of JSPR traded down $0.47 during mid-day trading on Monday, reaching $5.19. 118,213 shares of the stock traded hands, compared to its average volume of 266,628. The firm has a fifty day moving average price of $6.14 and a 200 day moving average price of $15.68. The company has a market cap of $77.89 million, a price-to-earnings ratio of -1.09 and a beta of 2.23. Jasper Therapeutics has a 1 year low of $4.55 and a 1 year high of $31.01.

Remove Ads

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.35). On average, sell-side analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current year.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. Braidwell LP bought a new position in shares of Jasper Therapeutics during the third quarter valued at about $9,091,000. Boxer Capital Management LLC bought a new position in shares of Jasper Therapeutics during the fourth quarter valued at about $7,483,000. Integral Health Asset Management LLC raised its stake in shares of Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock valued at $13,897,000 after acquiring an additional 300,000 shares during the last quarter. Ally Bridge Group NY LLC raised its stake in shares of Jasper Therapeutics by 82.7% during the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company's stock valued at $7,514,000 after acquiring an additional 180,852 shares during the last quarter. Finally, Soleus Capital Management L.P. raised its stake in shares of Jasper Therapeutics by 11.2% during the fourth quarter. Soleus Capital Management L.P. now owns 1,494,420 shares of the company's stock valued at $31,951,000 after acquiring an additional 150,755 shares during the last quarter. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.